Related Experiment Video
Updated: Jul 5, 2026

Surgical Techniques for Catheter Placement and 5/6 Nephrectomy in Murine Models of Peritoneal Dialysis
Published on: July 19, 2018
Inflammatory pattern in hemodiafiltration
Vincenzo Panichi1, Sabrina Paoletti, Cristina Consani
1Department of Internal Medicine, University of Pisa, Pisa, Italy.
Insights
Chronic inflammation, indicated by C-reactive protein (CRP) and interleukin-6 (IL-6), predicts mortality in hemodialysis (HD) patients. High-efficiency hemodiafiltration (HDF) improves survival, independent of dialysis dose.
Area of Science:
- Nephrology
- Inflammation Biology
- Clinical Medicine
Background:
- Chronic inflammation is linked to increased morbidity and mortality in hemodialysis (HD) patients.
- Elevated interleukin-6 (IL-6) and C-reactive protein (CRP) are associated with cardiovascular disease and low albumin (MIA syndrome).
- Dialysis modality, membrane type, and dialysate quality may influence chronic inflammation in HD patients.
Purpose of the Study:
- To investigate traditional and non-traditional risk factors for mortality and morbidity in HD patients.
- To evaluate the impact of different HD modalities on patient outcomes.
- To analyze the role of inflammation markers in predicting mortality within the HD population.
Main Methods:
- Observational, prospective trial (RISCAVID study) of the entire chronic HD population in Northwest Tuscany.
- 30-month follow-up data collection.
- Analysis of risk factors, including inflammatory markers (CRP, IL-6), and HD modalities (HD vs. HDF).
Main Results:
- Synergistic effect of CRP and pro-inflammatory cytokines identified as strong predictors of overall and cardiovascular mortality.
- High-efficiency hemodiafiltration (HDF) demonstrated an association with improved cumulative survival.
- This survival benefit from HDF was observed independently of the dialysis dose administered.
Conclusions:
- Inflammatory markers like CRP and IL-6 are critical predictors of mortality in hemodialysis patients.
- High-efficiency hemodiafiltration (HDF) offers a survival advantage over standard hemodialysis (HD).
- The benefits of HDF on survival are significant, irrespective of the delivered dialysis dose, highlighting its potential as a superior treatment modality.
Abstract:
Chronic inflammation may play an important role in early morbidity and mortality in hemodialysis (HD) patients. Interleukin-6 (IL-6) production is enhanced in long-term HD patients and this activated phase response has been shown to be a predictor of cardiovascular disease in the uremic syndrome as well as in the general population. Furthermore, IL-6 and C-reactive protein (CRP) have been negatively related to low serum albumin levels (MIA syndrome). Several studies have attempted to address the question as to whether the type of the dialysis membrane, the quality of the dialysate, and the dialysis technique may be responsible for the induction of a chronic inflammatory state. Recently, the Dialysis Outcomes and Practice Patterns Study (DOPPS) has shown that high-efficiency hemodiafiltration (HDF)- treated patients had a better survival than HD-treated patients accounting for sex, dialysis dose, co-morbid condition and country specificities. Here we report data from the RISCAVID study, an observational and prospective trial including the whole chronic HD population in the north-west part of Tuscany (1,235 million people). The aim of the study was to elucidate the relevance of traditional and non-traditional risk factors on mortality and morbidity in HD patients as well as the impact of different HD modalities. Data at 30 months from this study showed the synergic effect of CRP and pro-inflammatory cytokines as the strong predictors of overall and cardiovascular mortality. HDF was associated to an improved cumulative survival independently of dialysis dose.
Related Concept Videos
Hemodialysis I: Introduction
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Hemodialysis II: Procedure and Complications
Continuous Renal Replacement Therapy
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Acute Kidney Injury V: Interprofessional Care